TIGIT and neoplasm: Recent mechanistic studies show that combined blockade of PD-1 and TIGIT expands tumour-reactive CD8+ T-cell clones and restores effector function, supporting the rational design of triplet regimens (e.g. PD-1 + IL-33/ST2 + TIGIT) in biomarker-selected cohorts.